13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

Bristol-Myers Squibb BMY

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • It offers products for oncology, hematology, immunology, cardiovascular, neuroscience.
  • It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis.
  • In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE.
  • Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 5 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 16.04 FCF 10.18% Buyback -0.47%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Gotham Asset Management Joel Greenblatt 0.2% $52.3M 2026-03-31
Ariel Investments John Rogers 0.5% $43.8M 2026-03-31
Kahn Brothers Group 1.8% $10.3M 2026-03-31
Miller Value Partners Bill Miller 1.1% $4.2M 2026-03-31
Tweedy, Browne Company 0.1% $1.6M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 4 Last 3 13F filing periods
Net reducers 2 Last 3 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $79.8M Estimated from net added shares
Reduction amount $25.4M Estimated from net reduced shares
Net share change / base shares +78.7% +1,010,498 / 1,283,511
Gotham Asset Management Joel Greenblatt 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 14.8% 13F value change +$3.3M
13F 2025-12-31 Filed 2026-02-17
Minor increase Shares 12.1% 13F value change +$10.7M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 10.1% 13F value change +$10.1M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 607,986 Last 3 periods +254,221 (+41.8%) Total shares 862,207 Value $52.3M
Miller Value Partners Bill Miller 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Major reduction Shares -35.6% 13F value change -$1.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 108,000 Last 3 periods -38,500 (-35.6%) Total shares 69,500 Value $4.2M
Ariel Investments John Rogers 2 filing periods
13F 2025-12-31 Filed 2026-02-13
New Shares - 13F value change +$39.5M
13F 2026-03-31 Filed 2026-05-14
Minor reduction Shares -1.5% 13F value change +$4.3M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 0 Last 3 periods +721,731 (New) Total shares 721,731 Value $43.8M
Kahn Brothers Group 3 filing periods
13F 2025-09-30 Filed 2025-11-12
Major reduction Shares -50.5% 13F value change -$13.2M
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -25.8% 13F value change -$1.4M
13F 2026-03-31 Filed 2026-05-08
Major reduction Shares -15.7% 13F value change -$572,845
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 550,683 Last 3 periods -380,302 (-69.1%) Total shares 170,381 Value $10.3M
Tweedy, Browne Company 1 filing periods
13F 2026-03-31 Filed 2026-05-06
Major increase Shares 55.3% 13F value change +$678,026
Settlement As of 13F 2026-03-31 · Filed 2026-05-06
Base shares 16,842 Last 3 periods +9,316 (+55.3%) Total shares 26,158 Value $1.6M
Bridgewater Associates Ray Dalio 3 filing periods
13F 2025-03-31 Filed 2025-05-14
New Shares - 13F value change +$142.8M
13F 2025-06-30 Filed 2025-08-13
Major increase Shares 15.5% 13F value change -$17.6M
13F 2025-09-30 Filed 2025-11-13
Major reduction Shares -83.6% 13F value change -$105.1M
Settlement As of 13F 2025-09-30 · Filed 2025-11-13
Base shares 0 Last 3 periods +444,032 (New) Total shares 444,032 Value $20.0M
GQG Partners Rajiv Jain 3 filing periods
13F 2025-03-31 Filed 2025-05-13
New Shares - 13F value change +$733.3M
13F 2025-06-30 Filed 2025-08-13
Major reduction Shares -74.8% 13F value change -$593.3M
13F 2025-09-30 Filed 2025-11-13
Sold out Shares -100.0% 13F value change -$140.0M
Settlement As of 13F 2025-09-30 · Filed 2025-11-13
Base shares 0 Last 3 periods +0 (New) Total shares 0 Value $0

Recent mentions

No public mentions.